Role of The Osteoclast in Cancer

Abstract Osteoclasts play a pivotal role in healthy bone remodeling. However, often when cancer cells metastasize to bone the normal function of the osteoclast can be significantly disrupted. The cancer cells can secrete factors into the bone marrow microenvironment to promote osteoclast formation and activation, resulting in increased bone resorption. Cancers such as breast, prostate and multiple myeloma can develop osteolytic bone disease due to increased osteoclastic bone resorption. This can result in destructive and debilitating bone disease, often leading to increased fracture risks in patients.

• Publication year

  2019

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/B978-0-12-801238-3.11245-0
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer.

  2018cited by this paper
• The MIP‐1α autocrine loop contributes to decreased sensitivity to anticancer drugs

  2018cited by this paper
• Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models

  2018cited by this paper
• Therapeutic approaches for protecting bone health in patients with breast cancer.

  2018cited by this paper
• Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.

  2018cited by this paper
• Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line

  2018cited by this paper
• Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy

  2018cited by this paper
• Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.

  2017cited by this paper
• Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells

  2017cited by this paper
• CXCL12 and CXCR7 are relevant targets to reverse cell adhesion‐mediated drug resistance in multiple myeloma

  2017cited by this paper
• Integrin αvβ3 Signaling in Tumor-Induced Bone Disease

  2017cited by this paper
• Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

  2017cited by this paper
• Multiple myeloma

  2017cited by this paper
• Complications of bone metastases from malignant melanoma

  2017cited by this paper
• MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell Interactions.

  2017cited by this paper
• Phase 2 study of tabalumab, a human anti‐B‐cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma

  2017cited by this paper
• TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.

  2017cited by this paper
• Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.

  2016cited by this paper
• Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20

  2016cited by this paper
• Role of the RANK/RANKL pathway in breast cancer.

  2016cited by this paper
• Revisiting IL-6 antagonism in multiple myeloma.

  2016cited by this paper
• Parathyroid Hormone-Related Protein, Its Regulation of Cartilage and Bone Development, and Role in Treating Bone Diseases.

  2016cited by this paper
• Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial

  2016cited by this paper
• TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis

  2016cited by this paper
• Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow

  2016cited by this paper
• The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer*

  2016cited by this paper
• Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis.

  2016cited by this paper
• IL-1 drives breast cancer growth and bone metastasis in vivo

  2016cited by this paper
• Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622

  2016cited by this paper
• Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.

  2016cited by this paper
• Bone biology, signaling pathways, and therapeutic targets for osteoporosis.

  2015cited by this paper
• A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

  2015cited by this paper
• Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

  2015cited by this paper
• Blocking the ZZ Domain of Sequestosome1/p62 Suppresses Myeloma Growth and Osteoclast Formation In Vitro and Induces Dramatic Bone Formation in Myeloma-Bearing Bones In Vivo

  2015cited by this paper
• Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow

  2015cited by this paper
• Emerging therapies in bone metastasis.

  2015cited by this paper
• Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling

  2015cited by this paper
• Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche

  2015cited by this paper
• CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.

  2015cited by this paper
• Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.

  2015cited by this paper
• Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma

  2015cited by this paper
• Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts

  2015cited by this paper
• The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase

  2015cited by this paper
• Bisphosphonates and statins inhibit expression and secretion of MIP-1α via suppression of Ras/MEK/ERK/AML-1A and Ras/PI3K/Akt/AML-1A pathways.

  2015cited by this paper
• Novel therapeutic strategies for multiple myeloma.

  2015cited by this paper
• Targeting Bruton's tyrosine kinase in B cell malignancies

  2014cited by this paper
• Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

  2014cited by this paper
• Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model

  2014cited by this paper
• Notch signaling drives multiple myeloma induced osteoclastogenesis

  2014cited by this paper
• Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

  2014cited by this paper
• Efficacy of a Cathepsin K Inhibitor in a Preclinical Model for Prevention and Treatment of Breast Cancer Bone Metastasis

  2014cited by this paper
• Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis

  2014cited by this paper
• Sotatercept in patients with osteolytic lesions of multiple myeloma

  2014cited by this paper
• Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.

  2014cited by this paper
• Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics.

  2014cited by this paper
• Zerumbone Suppresses IL‐1β‐induced Cell Migration and Invasion by Inhibiting IL‐8 and MMP‐3 Expression in Human Triple‐negative Breast Cancer Cells

  2014cited by this paper
• Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo

  2014cited by this paper
• Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

  2013cited by this paper
• Alpha emitter radium-223 and survival in metastatic prostate cancer.

  2013cited by this paper
• Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.

  2013cited by this paper
• Role of Interleukin-1β in Radiation-Enhancement of MDA-MB-231 Breast Cancer Cell Invasion

  2013cited by this paper
• Optimal use of bisphosphonates in patients with multiple myeloma.

  2013cited by this paper
• BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.

  2013cited by this paper
• Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.

  2013cited by this paper
• A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

  2013cited by this paper
• Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease

  2013cited by this paper
• Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2012cited by this paper
• Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.

  2012cited by this paper
• Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

  2012cited by this paper
• Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases.

  2012cited by this paper
• The multifaceted actions of PTHrP in skeletal metastasis.

  2012cited by this paper
• Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation.

  2012cited by this paper
• Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: A potential therapeutic application in multiple myeloma

  2011cited by this paper
• Elevated cytokine production restores bone resorption by human Btk‐deficient osteoclasts

  2011cited by this paper
• Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.

  2011cited by this paper
• Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma

  2011cited by this paper
• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

  2011cited by this paper
• Treatment and prevention of bone complications from prostate cancer.

  2011cited by this paper
• SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 Axis

  2011cited by this paper
• MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases

  2011cited by this paper
• Cancer to bone: a fatal attraction

  2011cited by this paper
• Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

  2011cited by this paper
• RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II.

  2011cited by this paper
• Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.

  2011cited by this paper
• RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells

  2010cited by this paper
• The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.

  2010cited by this paper
• Systemic RANK‐Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts

  2010cited by this paper
• Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

  2010cited by this paper
• CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.

  2010cited by this paper
• A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.

  2010cited by this paper
• XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments.

  2010cited by this paper
• Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.

  2010cited by this paper
• MicroRNAs and their target gene networks in breast cancer

  2010cited by this paper
• Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

  2010cited by this paper
• Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.

  2010cited by this paper
• Latent bone metastasis in breast cancer tied to Src-dependent survival signals.

  2009cited by this paper
• Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.

  2009cited by this paper
• Pharmacologic Inhibition of the TGF-β Type I Receptor Kinase Has Anabolic and Anti-Catabolic Effects on Bone

  2009cited by this paper
• Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.

  2009cited by this paper
• Extracellular calcium promotes the migration of breast cancer cells through the activation of the calcium sensing receptor.

  2009cited by this paper

• The role of the bone microenvironment in regulating myeloma residual disease and treatment

  2022cites this paper
• The role of endolysosomal trafficking in anticancer drug resistance.

  2021cites this paper